• Jump to navigation (n)
  • Jump to content
  • Sitemap
Novalgen Novalgen
  • About us
    • Back
    • Overview
    • Our mission
    • Our team
    • Our history
    • Our investors
    • Our values
    • Community support
    • Social responsibility
    • Partnership & collaborations
  • Our technologies
    • Back
    • Overview
    • Our antibodies
    • Auto-regulation platform
    • Key capabilities
  • Patients & families
    • Back
    • Overview
    • Treatments
    • Patient organisations
    • Clinical trials
    • About disease areas
  • Pipeline
  • News & publications
    • Back
    • Overview
    • News
    • Publications
  • Careers
    • Back
    • Overview
    • Vacancies
  • Contact

News

Explore
  • 2023
  • 2022
  • 2021
  • 2020

NovalGen appoints Prof. David Venables to the Board of Directors

May 03, 2023

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors

Jan 09, 2023

Publications

Publications
Novalgen
  • About us
  • Our technologies
  • Patients & families
  • Pipeline
  • News
  • Careers
  • © Novalgen 2023
  • Privacy and cookies
  • Accessibility
  • Contact
  • LinkedIn
  • Home
  • About us
    • Back
    • About us
    • About us overview
    • Our mission
    • Our team
    • Our history
    • Our investors
    • Our values
    • Community support
    • Social responsibility
    • Partnership & collaborations
  • Our technologies
    • Back
    • Our technologies
    • Our technologies overview
    • Our antibodies
    • Auto-regulation platform
    • Key capabilities
  • Patients & families
    • Back
    • Patients & families
    • Patients & families overview
    • Treatments
    • Patient organisations
    • Clinical trials
    • About disease areas
  • Pipeline
  • News & publications
    • Back
    • News & publications
    • News & publications overview
    • News
    • Publications
  • Careers
    • Back
    • Careers
    • Careers overview
    • Vacancies
  • Contact